Posted in | News | Gold | Copper

Calibre Mining Receives Complete Assay Results from Primavera Prospect

Calibre Mining has obtained the entire assay results from the first two trenches that were dug on the new Primavera prospect, which is a gold-copper prospect located in the Borosi Project, northeast Nicaragua.

Stockwork quartz veining exposed in trench PRTR11-005

The company has encountered unbroken mineralization of gold and copper at both the trenches. It has cut 1.53 g/t gold, 680 ppm copper over 51.25 m in the trench PRTR11-005 and 0.78 g/t gold, 980 ppm copper over 107.0 m in the trench PRTR11-010.

The two trenches are situated around 100 m apart from the PRTR11-010 trending north to south and PRTR11-005 trending east to west. These trenches belong to five newly dug trenches, which are situated in an 850 x 300 m area of coincident copper and gold soil anomaly. Trench mineralization has featured copious stockwork veining and the region is considered to have potential porphyry related copper and gold mineralization. The mineralized interval is open along the trenches in both the directions and the company is continuing sampling and the trenching campaign.

Calibre’s Chairman has commented that the company is positive by the primary trench results from this wide gold-copper system. This fresh discovery has shown the underexplored nature of the significant Mining Triangle, northeast Nicaragua. Besides trenching at Primavera, the two drilling rigs are performing a resource definition drilling at the Riscos de Oro project.

This Primavera prospect depends on an option contract with B2Gold, in which the operator of the prospect is Calibre and B2Gold may possibly get a 51% interest by paying expenses of CDN $8 million by June 2014 for the detailed concessions in the Borosi region. When the earn-in is over, B2Gold may be chosen to perform a separate prospect in the concessions by means of a Preliminary Economic Assessment for a further 14% of interest in the prospect.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Calibre Mining Corp.. (2019, February 18). Calibre Mining Receives Complete Assay Results from Primavera Prospect. AZoMining. Retrieved on July 22, 2024 from https://www.azomining.com/News.aspx?newsID=5089.

  • MLA

    Calibre Mining Corp.. "Calibre Mining Receives Complete Assay Results from Primavera Prospect". AZoMining. 22 July 2024. <https://www.azomining.com/News.aspx?newsID=5089>.

  • Chicago

    Calibre Mining Corp.. "Calibre Mining Receives Complete Assay Results from Primavera Prospect". AZoMining. https://www.azomining.com/News.aspx?newsID=5089. (accessed July 22, 2024).

  • Harvard

    Calibre Mining Corp.. 2019. Calibre Mining Receives Complete Assay Results from Primavera Prospect. AZoMining, viewed 22 July 2024, https://www.azomining.com/News.aspx?newsID=5089.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.